Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Effectiveness of epcoritamab in a heterogeneous population with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) including post-chimeric antigen receptor T-cell therapy (CAR T) patients: Insights from the real-world epcoritamab patient characteristics and outcomes research (Real-EPCOR) study

View Full Paper
Ask AI
Bookmark
Share

Authors

YWYucai WangMJMonika JunAMAlex Mutebi

Discussion

Loading...

Member takes

Overview

Real-world evidence shows 50% overall response rate for patients with refractory DLBCL after receiving epcoritamab, indicating potential benefit post-CAR T therapy.

Key Points

  • Epcoritamab treatment achieved a 50% overall response rate in patients with relapsed/refractory DLBCL, highlighting its efficacy in challenging populations.
  • Among evaluable patients, 29% achieved complete response following epcoritamab, reinforcing its therapeutic potential in complex cases.
  • Analysis from a retrospective review included 34 patients with median age 67 and significant comorbidities, suggesting a high burden of disease in this cohort.
  • These findings underscore the importance of generating real-world evidence to inform the use of epcoritamab in diverse clinical settings.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e5e2https://doi.org/10.1182/blood-2025-8075
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Fixed-duration epcoritamab monotherapy induces high response and MRD-negativity rates in elderly patients with newly diagnosed large B-cell lymphoma (LBCL) and comorbidities: Results from EPCORE DLBCL-32025 · 2 citations
  2. 2Evaluation of prognostic factors and survival outcomes in patients with Relapsed/Refractory (R/R) large B-cell lymphomas (LBCLs) treated with epcoritamab2025
  3. 3Sustained remissions beyond 4 years with epcoritamab monotherapy: Long term follow-up results from the pivotal EPCORE NHL-1 trial in patients with relapsed or refractory large B-cell lymphoma2025
  4. 4Durable responses in patients with large B-cell lymphoma and 3+ prior lines of therapy who either paused or discontinued epcoritamab monotherapy while in complete response2025
  5. 5Rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma: Results of a multicenter phase II trial2025